Karen Schneck

A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes

Peggy L. Barrington, Jenny Y. Chien, H. D. Hollis Showalter et al. · Diabetes Obesity and Metabolism · 2011 · 109 citations

LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, showed a dose‐dependent effect on insulin secretion in healthy subjects

Peggy L. Barrington, Jenny Y. Chien, Fabián Tibaldi et al. · Diabetes Obesity and Metabolism · 2011 · 72 citations

Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling

Maria M. Posada, James A. Bacon, Karen Schneck et al. · Drug Metabolism and Disposition · 2014 · 57 citations

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Chris H. Takimoto, Lisa A. Hammond-Thelin, Jane E. Latz et al. · Clinical Cancer Research · 2007 · 47 citations

Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model

Karen Schneck, Xin Zhang, Robert J. Bauer et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2012 · 24 citations

Diabetes Management, Medicine, Insulin Management +9